Publications

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Oncology


Cellularly active N-hydroxyurea FEN 1 inhibitors block substrate entry to the active site    

PUBLISHED
Published online: Nature Chemical Biology; 15 August 2016, doi: 10.1038/nchembio.2148

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Stephen Durant, Claire McWhirter, Willem Nissink, Judit Debreczeni


CXCR2 inhibition profoundly suppresses metastases and improves immunotherapy in pancreatic ductal adenocarcinoma      

PUBLISHED
Cancer Cell, Volume 29, Issue 6, p832–845, 13 June 2016

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Simon T Barry, Zena Wilson


Overcoming mTOR resistance mutations with a new generation mTOR inhibitor    

PUBLISHED
Nature 534, 272–276 (09 June 2016) doi:10.1038/nature17963

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Sabina C Cosulich, Claire McWhirter, Derek G Barratt, Teresa Klinowska


Clinical development of new drug–radiotherapy combinations   

PUBLISHED
Published online 01 June 2016; Nature Reviews Clinical Oncology (2016) doi:10.1038/nrclinonc.2016.79

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Glen Clack


High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial    

PUBLISHED
Published Online May 13, 2016; doi: 10.1158/2159-8290.CD-15-1246

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Elaine Kilgour, Neil R Smith, Claire Rooney


Facilitating a Culture of Responsible and Effective Sharing of Cancer Genome Data    

PUBLISHED
Published online 5 May 2016; Nature Medicine 22, 464–471 (2016) doi:10.1038/nm.4089

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Carl Barrett


Challenges and strategies in anti-cancer nanomedicine development: an industry perspective

PUBLISHED
Published Online April, 2016; Advanced Drug Delivery Reviews http://dx.doi.org/10.1016/j.addr.2016.04.025

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Jennifer I Hare, Marianne B Ashford, Simon T Barry, Sanyogitta Puri


Defining actionable mutations for oncology therapeutic development

PUBLISHED
Published online 26 April 2016; Nature Reviews Cancer 16, 319–329 (2016) doi:10.1038/nrc.2016.35

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Hedley Carr, Robert McEwen


Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

PUBLISHED
Immunity: Volume 44, Issue 3, 15 March 2016, Pages 698–711
DOI: http://dx.doi.org/10.1016/j.immuni.2016.02.025

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Helen K Angell, Viia Valge-Archer


The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis

PUBLISHED
Science Translational Medicine  24 Feb 2016:
Vol. 8, Issue 327, pp. 327ra26
DOI: 10.1126/scitranslmed.aad6352

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Helen K Angell, Viia Valge-Archer


Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

PUBLISHED
Science Translational Medicine  10 Feb 2016:
Vol. 8, Issue 325, pp. 325ra17
DOI: 10.1126/scitranslmed.aad2355

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Simon T Barry, Susan Ashton, Philip J Jewsbury, Marianne B Ashford, Elaine Cadogan, Colin Howes, Jim Murray, Richard Goodwin, Urszula M Polanska, Corinne Reimer, Aaron Smith, John G Swales, Paula J Taylor, Joanne Wilson


Targeting the DNA damage response in cancer

PUBLISHED
19-Nov-15

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
O'Connor MJ


Patient-centric trials for therapeutic development in precision oncology

PUBLISHED
14-Oct-15

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Hollingsworth S.J.


MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

PUBLISHED
24-Sept-15

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Paul D. Smith


Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase

PUBLISHED
23-Jul-15

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Klein T, Vajpai N, Phillips J, Davies G, Holdgate G, Phillips C, Tucker J, Norman R, Scott A, Higazi D, Lowe D, Breeze A


c-kit+ cells do not generate lung epithelium during maintenance and repair

PUBLISHED
13-Jul-15: Nature Medicine doi:10.1038/nm.3888

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Wang QD


An analysis of the attrition of drug candidates from four major pharmaceutical companies

PUBLISHED
In press, published online 19 June 2015: 2015 Nature Reviews Drug Discovery 14, 475–486 (2015) doi:10.1038/nrd4609

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Mike Waring (Oncology iMed)


MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

PUBLISHED
May 2015: Nat Commun. 2015;6(7096). doi:10.1038/ncomms8096.

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Zheng Liu, Wei Zhu, Yue Wang, Bo Chen, Ronald Herbst, Laura Richman, Bahija Jallal, Yihong Yao (MedImmune)


Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

PUBLISHED
Published online 04 May 2015: Nature Medicine 21,560–562(2015) doi:10.1038/nm.3854

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Kenneth Tress (Oncology iMed)


Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations

PUBLISHED
May 2015: Sci Transl Med. 2015 May 20;7(288):288ra76. doi: 10.1126/scitranslmed.aaa4616.

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Brandon Higgs (MedImmune)


Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ

PUBLISHED
January 2015: Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008.

AREA
Oncology iMed

ASTRAZENECA/MEDIMMUNE AUTHOR
Simon Barry (Oncology iMed)


Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

PUBLISHED
January 2015:Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002.

AREA
Oncology

ASTRAZENECA/MEDIMMUNE AUTHOR
Susan Critchlow (Oncology iMed)


Cardiovascular and Metabolic diseases


C/EBP-Homologous Protein (CHOP) in Vascular Smooth Muscle Cells Regulates Their Proliferation in Aortic Explants and Atherosclerotic Lesions

PUBLISHED
January 2015: Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008.

AREA
Cardiovascular and Metabolic Disease

ASTRAZENECA/MEDIMMUNE AUTHOR
Alex Zhou (CVMD iMed)


Genetic lineage tracing identifies in situ Kit-expressing cardiomyocytes

PUBLISHED
4-Dec-15

AREA
Cardiovascular and Metabolic Disease

ASTRAZENECA/MEDIMMUNE AUTHOR
Wang QD              


Respiratory, Inflammation and Autoimmunity


Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function

PUBLISHED
12 May 2016

N Engl J Med 2016; 374:1811-1821DOI: 10.1056/NEJMoa1505971

AREA
Respiratory

ASTRAZENECA/MEDIMMUNE AUTHOR
Stephen I Rennard


TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26

PUBLISHED
July 2015: Nat Immunol. 2015;16(9):970-979. doi:10.1038/ni.3211.

AREA
Respiratory, Inflammation and Autoimmunity

ASTRAZENECA/MEDIMMUNE AUTHOR
Yong-Jun Liu (MedImmune)


Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

PUBLISHED
May 2015: Sci Transl Med. 2015 May 20;7(288):288ra76. doi: 10.1126/scitranslmed.aaa4616.

AREA
Inflammation and Autoimmunity

ASTRAZENECA/MEDIMMUNE AUTHOR
Tomas Mustelin (MedImmune)


Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

PUBLISHED
September 2015: Nature Communications

AREA

Respiratory, Inflammation and Autoimmunity

ASTRAZENECA/MEDIMMUNE AUTHOR
Cohen S, Scott I, Majithiya J, Rapley L, Kemp B, England E, Rees G, Overed-Sayer C, Woods J, Bond N, Seguy-Veyssier C, Embrey K, Sims D, Snaith M, Vousden K, Strain M, Chan D, Carmen S, Huntington C, Flavell L, Xu J, Popovic B, Vaughan T, Butler R, Lowe D, Higazi D, Corkill D, May R, Sleeman M, Mustelin T


IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

PUBLISHED
May 2015: Allergy, Volume 70, Issue 5, pages 556–567. doi: 10.1111/all.12593

AREA
Respiratory, Inflammation and Autoimmunity

ASTRAZENECA/MEDIMMUNE AUTHOR
Richard May (MedImmune)


Neuroscience


A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus  

PUBLISHED
Published online 9 May 2016; Nature Medicine 22, 649–656 (2016) doi:10.1038/nm.4096

AREA
Neuroscience

ASTRAZENECA/MEDIMMUNE AUTHOR
Nick Brandon, Alan J Cross


KCC2 activity is critical in limiting the onset and severity of status epilepticus

PUBLISHED
March 2015: Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3523-8. doi: 10.1073/pnas.1415126112.

AREA
Neuroscience

ASTRAZENECA/MEDIMMUNE AUTHOR
Nick Brandon (Neuroscience iMed)


BrainSeq: Neurogenomics to drive novel target discovery for Neuropsychiatric disorders

PUBLISHED
16-Dec-15

AREA
Neuroscience

ASTRAZENECA/MEDIMMUNE AUTHOR
Brandon N, Cross A, Wang Q

Infection and Vaccines


ESKAPEing the labyrinth of antibacterial discovery

PUBLISHED
03-Jul-15: Nature Reviews Drug Discovery doi:10.1038/nrd4572

AREA
Infection and Vaccines

ASTRAZENECA/MEDIMMUNE AUTHOR
Tommasi R, Brown D, Walkup G, Manchester J, Miller A


Translating slow-binding inhibition kinetics into cellular and in vivo effects

PUBLISHED
20-Apr-15

AREA
Infection and Vaccines

ASTRAZENECA/MEDIMMUNE AUTHOR
Walkup G,  You Z, Ross P, Hale M, O’Donnell J, Ehmann D, Schuck V, Buurman E, Choy A, Hajec L, Murphy-Benenata K, Marone V, A Patey S, Grosser L, Johnstone M, , Fisher S                  


Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate

PUBLISHED
31 March 2015

AREA
Infection iMed and Drug Safety and Metabolism

ASTRAZENECA/MEDIMMUNE AUTHOR
Hameed S, Solapure S, Patil V, Bharath S, Murugan K, Viswanath P, Puttur J, Srivastava A, Bellale E, Panduga V, Shanbag G, Awasthy D, Landge S, Sapna Morayya, Krishna Koushik, Ramanatha Saralaya, Anandkumar Raichurkar, Nikhil Rautela, Nilanjana Roy Choudhury, Anisha Ambady, Radha Nandishaiah, Jitendar Reddy, K. R. Prabhakar, Sreenivasaiah Menasinakai, Suresh Rudrapatna, Monalisa Chatterji, Balachandra Bandodkar, Kakoli Mukherjee, V. Balasubramanian, Peter Warner, Vinayak Hosagrahara,Adam Dudley, Pravin S. Iyer, Shridhar Narayanan, Vasan K. Sambandamurthy, Lyn Rosenbrier-Ribeiro, Kevin Hickling, Stefan Kavanagh & Robert E. McLaughlin


Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge

PUBLISHED
31-Mar-15

AREA
Infection and Vaccines

ASTRAZENECA/MEDIMMUNE AUTHOR
Hameed S, Solapure S, Patil V, Bharath S, Murugan K, Viswanath P, Puttur J, Srivastava A, Bellale E, Panduga V, Shanbag G, Awasthy D, Landge S, Sapna Morayya, Krishna Koushik, Ramanatha Saralaya, Anandkumar Raichurkar, Nikhil Rautela, Nilanjana Roy Choudhury, Anisha Ambady, Radha Nandishaiah, Jitendar Reddy, K. R. Prabhakar, Sreenivasaiah Menasinakai, Suresh Rudrapatna, Monalisa Chatterji, Balachandra Bandodkar, Kakoli Mukherjee, V. Balasubramanian, Peter Warner, Vinayak Hosagrahara,Adam Dudley, Pravin S. Iyer, Shridhar Narayanan, Vasan K. Sambandamurthy, Lyn Rosenbrier-Ribeiro, Kevin Hickling, Stefan Kavanagh & Robert E. McLaughlin


Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge

PUBLISHED
March 2015: J Clin Invest. 2015;125(4):1637–1647. doi:10.1172/JCI78450.

AREA
Infection and Vaccines

ASTRAZENECA/MEDIMMUNE AUTHOR
Jeanne H. Schickli, Roderick S. Tang, Jasmine Kaur, Heather Lawlor, Michael P. McCarthy, Gary Van Nest (MedImmune)

Personalised Health Care and Biomakers


Aberrant splicing of U12-type introns is the hallmark of ​ZRSR2 mutant myelodysplastic syndrome

PUBLISHED
14-Jan-15: Nature Communications

AREA
Personalised Healthcare and Biomarkers

ASTRAZENECA/MEDIMMUNE AUTHOR
Kohlmann A

Early Discovery


Cell permeability beyond the rule of 5 

PUBLISHED
Advanced Drug Delivery Reviews; Volume 101, 1 June 2016, Pages 42–61. http://dx.doi.org/10.1016/j.addr.2016.03.013

AREA
Early Discovery

ASTRAZENECA/MEDIMMUNE AUTHOR
Bjorn Over